Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the present study, we examined the effect of intracerebroventricularly (i.c.v.) injected choline on both basal and stimulated
oxytocin
release in conscious rats. I.c.v. injection of choline (50-150 micrograms) caused time- and dose-dependent increases in plasma
oxytocin
levels under normal conditions. The increase in plasma
oxytocin
levels in response to i.c.v. choline (150 micrograms) was greatly attenuated by the pretreatment of rats with atropine (10 micrograms; i.c.v.), muscarinic receptor antagonist.
Mecamylamine
(50 micrograms; i.c.v.), a nicotinic receptor antagonist, failed to suppress the effect of 150 micrograms choline on
oxytocin
levels. Pretreatment of rats with 20 micrograms of hemicholinium-3 (HC-3), a specific inhibitor of choline uptake into nerve terminals, greatly attenuated the increase in plasma
oxytocin
levels in response to i.c.v. choline injection. Osmotic stimuli induced by either oral administration of 1 ml hypertonic saline (3 M) following 24-h dehydration of rats (type 1) or an i.c.v. injection of hypertonic saline (1 M) (type 2) increased plasma
oxytocin
levels significantly, but hemorrhage did not alter basal
oxytocin
concentrations. The i.c.v. injection of choline (50, 150 micrograms) under these conditions caused an additional and significant increase in plasma
oxytocin
concentrations beyond that produced by choline in normal conditions. These data show that choline can increase plasma
oxytocin
concentrations through the stimulation of central cholinergic muscarinic receptors by presynaptic mechanisms and enhance the stimulated
oxytocin
release.
...
PMID:Intracerebroventricular injection of choline increases plasma oxytocin levels in conscious rats. 886 61